Current Clinical Trials
Where can I find information about clinical trials of targeted therapies?
Now Enrolling: Oncology Clinical Trials at Salib Oncology
We are currently enrolling participants for the following IRB-approved research studies. Qualified participants may receive study-related care and compensation. If you or someone you know may be eligible, please reach out for a confidential pre-screening.
1. Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Study Title: Phase 3 Study of Tarlatamab Therapy in Patients With LS-SCLC Post-Chemoradiation
Who Can Join:
- Diagnosed with Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
- Completed treatment with concurrent chemotherapy and radiotherapy
- Currently not experiencing disease progression
Purpose: To assess the safety and effectiveness of Tarlatamab in individuals who have completed standard chemoradiation for LS-SCLC.
Location: 3465 Nazareth Road, Suite 102 Easton, PA 18045
Compensation: Provided for eligible participants
Contact:
info@goodclinicaltrials.com |
Phone:
(833) 330-0930 |
Text:
(717)-819-9982
2. Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Study Title: Phase 3 Study of Sacituzumab Govitecan vs. Standard of Care in ES-SCLC
Who Can Join:
- Diagnosis of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
- Progressed after 1 prior platinum-based chemotherapy, with or without anti-PD-1/PD-L1 therapy
- Prior treatment must include at least 2 cycles
Purpose: To compare investigational therapy (Sacituzumab Govitecan) with current standard treatments in patients with previously treated ES-SCLC.
Location: 3465 Nazareth Road, Suite 102 Easton, PA 18045
Compensation: Provided for eligible participants
Contact:
info@goodclinicaltrials.com |
Phone:
(833) 330-0930 |
Text:
(717)-819-9982
3. Advanced or Metastatic Non-Squamous NSCLC
Status: Enrollment opens late Q4 2025
Study Title: Phase 2 Study of ABBV-400 + Budigalimab in Advanced or Metastatic NSCLC
Who Can Join (Once Open):
• Diagnosed with locally advanced or metastatic non-squamous NSCLC
• No prior treatment for advanced disease
• No actionable genetic mutations (e.g., EGFR, ALK)
Purpose: To evaluate the safety and effectiveness of ABBV-400 and Budigalimab as a first-line treatment for advanced NSCLC.
Location: 3465 Nazareth Road, Suite 102 Easton, PA 18045
Compensation: Provided for eligible participants
Contact:
info@goodclinicaltrials.com |
Phone:
(833) 330-0930 | Text:
(717)-819-9982
Contact Us Today:
Located: 3465 Nazareth Road, Suite 102 Easton, PA 18045
Phone: (833) 330-0930
Text: 717-819-9982
Email: info@goodclinicaltrials.com